New Opioid Approval Standard Intended To Drive Development Into Other Therapeutics
Executive Summary
US FDA explored whether existing law allowed for the higher standard, but determined new authority granted by Congress was necessary.
You may also be interested in...
New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks
US FDA’s mandated labeling changes come after the agency required manufacturers to provide mail-back envelopes for opioid disposal.
Califf Hints At Labeling Changes For Opioids And Chronic Pain
Califf also said the agency is open to endpoints other than abstinence for new opioid use disorder treatments at the fourth annual NIH HEAL Initiative Investigator Meeting.
Califf Urges Congressional Patience On Opioid Actions
Labeling changes for the pain products remain in active discussion, the US FDA commissioner tells the Senate Health, Education, Labor and Pensions Committee during a hearing on the monkeypox outbreak.